Difference between revisions of "Atezolizumab (Tecentriq)"
Jump to navigation
Jump to search
m (PeterYang moved page MPDL3280A to Atezolizumab (MPDL3280A)) |
|||
| Line 1: | Line 1: | ||
| − | == | + | ==General information== |
| − | + | Class/mechanism: PD-L1 antibody. Atezolizumab targets PD-L1 (programmed cell death-1 ligand 1) which is expressed on tumor cells and tumor-infiltrating immune cells, preventing it from binding to PD-1 and B7.1 on T-cells. By interfering with the binding of PD-L1 to T-cell receptors, it can cause upregulation of the anti-tumor immune response.<ref>Naiyer A. Rizvi, Laura Quan Man Chow, Luc Yves Dirix, Scott N. Gettinger, Michael S. Gordon, Fairooz F. Kabbinavar, Joachim Von Pawel, Jean-Charles Soria, Colombe Chappey, Ahmad Mokatrin, Alan Sandler, Daniel Waterkamp, David R. Spigel. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC). 2014 ASCO Annual Meeting abstract TPS8123. [http://meetinglibrary.asco.org/content/128983-144 link to abstract]</ref><ref>[http://www.roche.com/media/store/releases/med-cor-2015-08-17.htm Pivotal Phase II study showed Roche's investigational immunotherapy atezolizumab shrank tumours in people with a specific type of lung cancer] Roche.com, 8/17/2015.</ref> | |
| + | |||
| + | ==Clinical trials== | ||
| + | *[https://clinicaltrials.gov/ct2/show/NCT02031458 A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - "BIRCH"] | ||
==Also known as== | ==Also known as== | ||
| − | RG7446 | + | *RG7446 |
| + | |||
| + | ==References== | ||
| + | <references/> | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
Revision as of 18:34, 31 October 2015
General information
Class/mechanism: PD-L1 antibody. Atezolizumab targets PD-L1 (programmed cell death-1 ligand 1) which is expressed on tumor cells and tumor-infiltrating immune cells, preventing it from binding to PD-1 and B7.1 on T-cells. By interfering with the binding of PD-L1 to T-cell receptors, it can cause upregulation of the anti-tumor immune response.[1][2]
Clinical trials
Also known as
- RG7446
References
- ↑ Naiyer A. Rizvi, Laura Quan Man Chow, Luc Yves Dirix, Scott N. Gettinger, Michael S. Gordon, Fairooz F. Kabbinavar, Joachim Von Pawel, Jean-Charles Soria, Colombe Chappey, Ahmad Mokatrin, Alan Sandler, Daniel Waterkamp, David R. Spigel. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC). 2014 ASCO Annual Meeting abstract TPS8123. link to abstract
- ↑ Pivotal Phase II study showed Roche's investigational immunotherapy atezolizumab shrank tumours in people with a specific type of lung cancer Roche.com, 8/17/2015.